67 Recruiting Studies Using Ibrutinib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Ibrutinib
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
📍 The University of Arizona Cancer Center - North Campus /ID# 242219 — Tucson, Arizona
Non-Hodgkin Lymphoma
View Study & Checklist ➔Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
📍 City of Hope Medical Center — Duarte, California
Recurrent Transformed Chronic Lymphocytic Leukemia
View Study & Checklist ➔Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
📍 Alaska Oncology and Hematology, LLC — Anchorage, Alaska
Lymphoma, Mantle-Cell
View Study & Checklist ➔Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Primary Central Nervous System Lymphoma
View Study & Checklist ➔Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
📍 Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
Lymphoma
View Study & Checklist ➔Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
📍 10 sites incl TX, WA, VA, and NV — Dallas, Texas
Breast Neoplasms
View Study & Checklist ➔Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
View Study & Checklist ➔Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Prolymphocytic Leukemia
View Study & Checklist ➔Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
📍 Research Site — Phoenix, Arizona
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
📍 City of Hope Medical Center — Duarte, California
B-Cell Prolymphocytic Leukemia
View Study & Checklist ➔ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
📍 Dana Farber Cancer Institute — Boston, Massachusetts
Recurrent Chronic Lymphoid Leukemia
View Study & Checklist ➔Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
Mantle Cell Lymphoma
View Study & Checklist ➔Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
📍 City of Hope National Medical Center — Duarte, California
Mantle Cell Lymphoma
View Study & Checklist ➔Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
Blastoid Variant Mantle Cell Lymphoma
View Study & Checklist ➔Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Hairy Cell Leukemia
View Study & Checklist ➔Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
📍 M D Anderson Cancer Center — Houston, Texas
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
📍 Icahn School of Medicine at Mount Sinai — New York, New York
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
📍 MedStar Georgetown University Hospital — Washington D.C., District of Columbia
Recurrent Chronic Lymphocytic Leukemia
View Study & Checklist ➔Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Lymphoma
View Study & Checklist ➔Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
📍 University of Chicago Comprehensive Cancer Center — Chicago, Illinois
Recurrent Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Central Nervous System Lymphoma
View Study & Checklist ➔A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
📍 Massachusetts General Hospital — Boston, Massachusetts
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Stage I Chronic Lymphocytic Leukemia
View Study & Checklist ➔PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
📍 Ohio State University Medical Center — Columbus, Ohio
Prolymphocytic Leukemia
View Study & Checklist ➔A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
📍 University of Miami Sylvester Comprehensive Cancer Center — Coral Gables, Florida
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
📍 The Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Mantle Cell Lymphoma
View Study & Checklist ➔Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
📍 UC San Diego Moores Cancer Center — La Jolla, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Anemia
View Study & Checklist ➔A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
📍 George Washington Cancer Center — Washington D.C., District of Columbia
Marginal Zone Lymphoma
View Study & Checklist ➔Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
CCND1 Positive
View Study & Checklist ➔Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
View Study & Checklist ➔Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
📍 Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center, The Roy & Patricia Disney Family Cancer Center — Burbank, California
Lymphoma, B-Cell
View Study & Checklist ➔Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
📍 The Oncology Institute Clinical Research — Cerritos, California
Leukemia, Lymphocytic, Chronic, B-Cell
View Study & Checklist ➔Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
📍 Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center — Cleveland, Ohio
Glioblastoma
View Study & Checklist ➔Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
📍 UC San Diego Moores Cancer Center — La Jolla, California
AIDS-Related Lymphoma
View Study & Checklist ➔Ibrutinib + Venetoclax in Untreated WM
📍 Massachusetts General Hospital — Boston, Massachusetts
Waldenstrom Macroglobulinemia
View Study & Checklist ➔Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
📍 Washington University School of Medicine — St Louis, Missouri
Recurrent Mantle Cell Lymphoma
View Study & Checklist ➔Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma
📍 Mayo Clinic in Arizona — Scottsdale, Arizona
Grade 3a Follicular Lymphoma
View Study & Checklist ➔Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
📍 Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania
Non-Hodgkin's Lymphoma
View Study & Checklist ➔Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma
📍 MedStar Georgetown University Hospital — Washington D.C., District of Columbia
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
View Study & Checklist ➔Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
📍 University of California LA — Los Angeles, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
📍 Winship Cancer Center of Emory University — Atlanta, Georgia
Classical Hodgkin Lymphoma
View Study & Checklist ➔Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
📍 University of California, San Francisco (UCSF) Fresno — Fresno, California
Ann Arbor Stage II Follicular Lymphoma
View Study & Checklist ➔Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
Mantle Cell Lymphoma
View Study & Checklist ➔A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
📍 Norton Cancer Institute — Louisville, Kentucky
Leukemia, Lymphocytic, Chronic, B-Cell
View Study & Checklist ➔Mosunetuzumab for CLL MRD Clearance
📍 Brigham & Women's Hospital — Boston, Massachusetts
Leukemia
View Study & Checklist ➔A Long-term Extension Study of PCI-32765 (Ibrutinib)
📍 City of Hope Cancer Center — Duarte, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
📍 USA Mitchell Cancer Institute ( Site 0014) — Mobile, Alabama
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
📍 Augusta University, Georgia Cancer Center — Augusta, Georgia
Ependymoma
View Study & Checklist ➔Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
📍 Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
Non-hodgkin Lymphoma
View Study & Checklist ➔Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
📍 University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota
Recurrent Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
📍 OHSU Knight Cancer Institute — Portland, Oregon
Mantle Cell Lymphoma
View Study & Checklist ➔A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
📍 San Francisco VA Medical Center, San Francisco, CA — San Francisco, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Pembrolizumab, Ibrutinib and Rituximab in PCNSL
📍 Dana Farber Cancer Institute — Boston, Massachusetts
Primary Central Nervous System Lymphoma
View Study & Checklist ➔CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
📍 St. Joseph's Hospital and Medical Center — Phoenix, Arizona
Relapsed Hematologic Malignancy
View Study & Checklist ➔A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Primary Central Nervous System Lymphoma (PCNSL)
View Study & Checklist ➔Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
📍 Banner University Medical Center - Tucson — Tucson, Arizona
High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements
View Study & Checklist ➔Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
📍 Banner University Medical Center - Tucson — Tucson, Arizona
Lymphoplasmacytic Lymphoma
View Study & Checklist ➔A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
📍 Pacific Cancer Medical Center, Inc — Anaheim, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Lymphoma
View Study & Checklist ➔